Department of Oral and Dental Science, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK.
Eur J Health Econ. 2010 Dec;11(6):525-31. doi: 10.1007/s10198-009-0207-9. Epub 2009 Nov 21.
Neovascular age-related macular degeneration (nvAMD) is a chronic, progressive disease of the central retina, and its prevalence is expected to rise with the ageing population. Using a bottom-up approach based on retrospective data, this cross-sectional study estimated average annual direct costs of nvAMD to be £4,047, and average annual indirect costs to be £449. An attempt to measure intangible costs through willingness-to-pay yielded a lower response rate and estimated intangible costs to be 11.5% of monthly income. Direct costs were significantly higher for male participants, for those who have mild or moderate visual impairment in both eyes, and for those who have been diagnosed for a shorter time. The findings of this study suggest that the availability of early diagnosis, effective treatment, support services, and sustained research into the management of nvAMD may reduce the burden of visual impairment caused by nvAMD to affected individuals and the state.
新生血管性年龄相关性黄斑变性（nvAMD）是一种慢性、进行性的中心性视网膜疾病，预计随着人口老龄化，其患病率将会上升。本横断面研究采用自下而上的方法，基于回顾性数据，估算 nvAMD 的年均直接成本为 4047 英镑，年均间接成本为 449 英镑。通过支付意愿来衡量无形成本的尝试得到了较低的响应率，并估计无形成本占月收入的 11.5%。男性参与者、双眼有轻度或中度视力障碍以及诊断时间较短的参与者的直接成本明显更高。本研究结果表明，早期诊断、有效治疗、支持服务的提供以及对 nvAMD 管理的持续研究，可能会减轻 nvAMD 给患者个人和国家带来的视力损害负担。
